Soligenix (SNGX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SNGX Soligenix

Watchlist

3.1601
-0.1499-4.53%

Close Dec 13 16:00 ET

3.1601
0.00000.00%

Post 20:01 ET

7.93MMarket Cap-0.49P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Soligenix Announces Analysis From Protocol HPN-CTCL-04
TipRanksDec 2 07:40 ET
Express News | Soligenix Announced That Analysis Of The Post-treatment Data From The Open-label Study Comparing HyBryte (Synthetic Hypericin) To Valchlor (Mechlorethamine) Has Demonstrated Continued Improvement In HyBryte-treated Patients And Their Individual...
BenzingaDec 2 07:40 ET
Express News | Soligenix Inc: Hybryte Was Well Tolerated in All Patients
ReutersDec 2 07:33 ET
Express News | Soligenix: 1 Of 5 Patients Receiving Valchlor Had to Be Withdrawn From Trial Due to a Clinically Significant Allergic Contact Dermatitis
ReutersDec 2 07:32 ET
Express News | Hybryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment
ReutersDec 2 07:30 ET
Soligenix Reveals Formation Of European Medical Advisory Board To Provide Additional Medical/Clinical Strategic Guidance; Phase 3 Clinical Study Of HyBryte In CTCL Initiating In 2024
BenzingaNov 19 07:40 ET

Comments

Trytosaveabit

Dec 2 06:46

This is how original PR should been! Hehehe

$Soligenix (SNGX.US)$ Soligenix Announced That Analysis Of The Post-treatment Data From The Open-label Study Comparing HyBryte (Synthetic Hypericin) To Valchlor (Mechlorethamine) Has Demonstrated Continued Improvement In HyBryte-treated Patients And Their Individual Lesions Even After Stopping Treatment

Trytosaveabit

Dec 2 06:34

Update

$Soligenix (SNGX.US)$ Reuters· just
Soligenix: 1 Of 5 Patients Receiving Valchlor Had to Be Withdrawn From Trial Due to a Clinically Significant Allergic Contact Dermatitis

Trytosaveabit

Dec 2 06:32

Update

$Soligenix (SNGX.US)$ Reuters
1 min ago
Hybryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Jaguar8

Dec 2 06:31

NEWS

$Soligenix (SNGX.US)$
HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment
Monday, 2nd December at 7:30 am
Significant Efficacy against Plaque Lesions Also Demonstrated with HyBryte™
PRINCETON, N.J., Dec. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that analysis of t...

Teddy123

Nov 20 04:46

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

$Soligenix (SNGX.US)$
19/11/2024 - 20:30
Phase 3 clinical study of HyBryte™ in CTCL initiating in 2024
PRINCETON, N.J., Nov. 19, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a European M...

Heat List

Overall

No Data